Showing 1 - 10 of 15
Persistent link: https://www.econbiz.de/10010416365
Persistent link: https://www.econbiz.de/10011911607
Persistent link: https://www.econbiz.de/10009509405
Persistent link: https://www.econbiz.de/10009548834
Persistent link: https://www.econbiz.de/10009530131
"Substandard and counterfeit drugs represent a global public health crisis. However, there is little economic analysis of the market given the paucity of data. Focusing on 8 drug types on the WHO-approved medicine list, we constructed an original dataset of 899 drug samples from 17 low- and...
Persistent link: https://www.econbiz.de/10008933532
Persistent link: https://www.econbiz.de/10010345596
Pharmaceutical products can be of poor quality either because they contain zero correct active ingredient (referred to as "counterfeit") or because they contain a non-zero but incorrect amount of the right active ingredient (referred to as "substandard"). While both types of poor-quality drugs...
Persistent link: https://www.econbiz.de/10013036913
Focusing on 8 drug types on the WHO-approved medicine list, we constructed an original dataset of 899 drug samples from 17 low- and median-income countries and tested them for visual appearance, disintegration, and analyzed their ingredients by chromatography and spectrometry. Fifteen percent of...
Persistent link: https://www.econbiz.de/10012461804
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in...
Persistent link: https://www.econbiz.de/10012458199